Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Buy the report here. EU and Asia.

Hormones 113

Hormones Contract Manufacturing Manufacturing Development 113

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Buy the report here. EU and Asia. EU and Asia.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Buy the report here.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

Roots Analysis

FEBRUARY 26, 2024

In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017. Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

Roots Analysis

FEBRUARY 27, 2024

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

The Pharma Data

AUGUST 3, 2021

Boehringer Ingelheim also announced the planned initiation of the innovative CONNEX Phase III clinical trial program assessing the safety and efficacy of BI 425809, a novel glycine transporter-1 (GlyT1) inhibitor, for improving cognition in adults with schizophrenia. In the first six months, the company generated net sales of 9.8 billion EUR.

Development 52

Development Research Contract Manufacturing Sales 52

The Pharma Data

MARCH 16, 2021

Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim’s deep experience in central nervous system (CNS) drug discovery and development alongside Lieber’s expertise in centrally acting COMT inhibitors. The Lieber Institute for Brain Development. Weinberger, M.D.,

Development 52

Development Contract Manufacturing Licensing Licensing 52

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

JULY 21, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union. This press release features multimedia.

Manufacturing 52

Manufacturing Vaccination Vaccine Clinical Trials 52

pharmaphorum

JANUARY 7, 2021

It gave CureVac €75 million in funding to develop CVnCoV last July, adding to around €100 million provided by the German government in 2020. At last count, there are more than 60 coronavirus vaccines at in clinical development around the world, with another 170 in preclinical testing, according to the World Health Organization (WHO).

Vaccination 105

Vaccination Vaccine Contract Manufacturing Development 105

The Pharma Data

MARCH 1, 2022

We are excited to see how our technology and global biobank partnerships can transform research capabilities for Boehringer Ingelheim and deliver powerful impacts for clinical development pipelines across disease areas.”. “We Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective.

Biobanking 52

Biobanking Genome Genomics Genome Project 52

The Pharma Data

MARCH 2, 2021

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. Financial terms of the new agreement are not disclosed.

In-Vivo 52

In-Vivo Contract Manufacturing Bioinformatics Clinical Development 52

The Pharma Data

NOVEMBER 5, 2020

Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Updates from the clinical pipeline include: Dupixent ® (dupilumab). Corporate and Business Development Update. Business Highlights.

Sales 52

Sales Production Manufacturing Antibody 52

The Pharma Data

MARCH 29, 2022

With Veeva Development Cloud, Boehringer Ingelheim aims to establish a connected technology landscape for agile collaboration that can accelerate the development of novel medicines Transformation focuses on reducing complexity and developing an innovative, digital culture to better understand and address unmet medical needs.

Development 52

Development Contract Manufacturing Medicine Clinical Development 52

pharmaphorum

NOVEMBER 12, 2020

In 2018, it bought Element Genomics – a spin-out of Duke University in the US – to add genome-editing technologies, and has also been growing its internal exercise at its Boston R&D hub, although so far it hasn’t advanced and gene therapies into clinical development.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

The Pharma Data

JANUARY 27, 2021

The two-hour event will cover various topics, including an overview of the Company’s board and executive leadership, its commitment to environment, social and governance (ESG) matters, and progress updates on the Company’s critical care programs, manufacturing and distribution approach, and commercial readiness plans. 28, 2021 11:00 UTC.

Clinical Trials 52

Clinical Trials Clinical Trials Production Trials 52

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Shah previously served as Chief Executive Officer and a member of the board of directors of BioMotiv, an accelerator company aligned with the Harrington Project for Discovery & Development, a U.S.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

Pharmaceutical Technology

NOVEMBER 30, 2022

Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Manufacturing for Wegovy was also hit when a contract manufacturer in charge of syringe filling halted deliveries due to issues with good manufacturing practices.

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Manufacturing for Wegovy was also hit when a contract manufacturer in charge of syringe filling halted deliveries due to issues with good manufacturing practices.

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246